Vice President, Clinical Operations
Deepali Suri joined Sunesis in 2018 as Vice President, Clinical Operations. Prior to Sunesis, she served as Executive Director, Clinical Operations at Pharmacyclics (AbbVie), where she led PhI-III Global Clinical Trials for Ibrutinib (IMBRUVICA®) and Abexinostat (HDAC inhibitor). At Pharmacyclics, she was a key contributor leading up to the regulatory approval of Ibrutinib in treatment naïve CLL/SLL, MZL and other indications. Previously, she worked at PPD, Inc., a Global CRO, leading various Ph I-III trials from startup to closeout. Deepali has over 15 years of experience in novel drug development spanning multiple therapeutic areas including oncology, hematology, ophthalmology, endocrine, infectious diseases and cardiovascular therapeutics. Deepali started her career with Pharmacia (Pfizer) where she worked on the development of Sunitimib (SUTENT®) and Atorvastatin (LIPITOR®). Deepali holds Masters in Pharmacy (Pharmacology) from Delhi University.